Thyrocare Technologies has announced that its Board of Directors will convene on May 07, 2026. The primary agenda for this meeting includes the review and approval of the company’s audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026. Additionally, the board will evaluate and potentially recommend a final dividend for the financial year 2025-26.
Meeting Agenda and Financial Approval
Thyrocare Technologies has scheduled a meeting of its Board of Directors for May 07, 2026. During this session, the leadership team will finalize and approve the audited financial results covering both the final quarter (Q4) and the full fiscal year ending March 31, 2026. The review will encompass both standalone and consolidated financial performance, providing a comprehensive outlook on the company’s fiscal health for 2025-26.
Dividend Consideration
A key highlight of the upcoming board meeting is the proposal for a final dividend for the 2025-26 financial year. Investors and stakeholders are awaiting the board’s decision, which will be determined during these proceedings, following the review of the year’s profitability and capital allocation requirements.
Trading Window Update
In adherence to corporate governance standards, the company’s trading window for equity shares remains closed for all designated persons and their immediate relatives. The closure, which commenced on April 01, 2026, is set to continue until 48 hours after the official announcement of the financial results. This measure ensures strict compliance with insider trading protocols during the sensitive pre-result period.
Source: BSE
